Clinical Social Workers in Bernalillo, NM Accepting Medicare
4 Clinical Social Workers found. Showing 1 - 4
 Karen S. Szlapka, LMHC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 872 S Camino Del Pueblo, Bernalillo, NM 87004 Phone: 505-867-2383 Fax: 505-867-7293 |
Margaret A. Reade, LISW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 872 S Camino Del Pueblo, Bernalillo, NM 87004 Phone: 505-867-2383 Fax: 505-867-7293 |
 Michael Ollom, LISW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 872 S Camino Del Pueblo, Bernalillo, NM 87004 Phone: 505-867-2383 Fax: 505-867-7293 |
Ms. Debra D Alvarado, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 872 S Camino Del Pueblo, Bernalillo, NM 87004 Phone: 505-274-9653 |
News Archive
NuGEN Technologies launches its next generation Ovation RNA-Seq System
NuGEN Technologies, Inc., a pace-setter in genomic sample preparation, enters the next generation sequencing (NGS) market today with its Ovation RNA-Seq System, a revolutionary method of sample preparation that broadens research horizons with a more comprehensive representation of the transcriptome created from samples of a few hundred picograms.
Newly discovered nerve cells trigger locomotion, supply the brain with speed-related information
Scientists at the German Center for Neurodegenerative Diseases and the University of Bonn led by Prof. Stefan Remy report on this in the journal "Neuron". Their investigations give new insights into the workings of spatial memory. Furthermore, they could also help improve our understanding of movement related symptoms associated with Parkinson's disease.
Arthritis of the knee may be a sign of non-small cell lung cancer
Arthritis of the knee may be the first sign of a type of lung cancer that is hard to treat in heavy smokers, suggests research published ahead of print in the Annals of the Rheumatic Diseases.
EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis
S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.
› Verified 2 days ago
Counselors
Pharmacists
Occupational Therapists
Psychologists
Clinical Social Workers
Dentists